This article is more than 5 years old. Information may no longer be current.
Wilkinson leaving Actavis to head Impax Laboratories
Click Here to Manage Email Alerts
Actavis announced that G. Frederick Wilkinson, president of Actavis Global R&D, will leave the company to become president and chief executive officer of Impax Laboratories.
“Over the past five years, Fred has played an essential role in our evolution from a primarily generics company to a leading specialty pharmaceutical company,” Paul M. Bisaro, chairman and chief executive officer of Actavis, said in a press release. “He was also instrumental in establishing our biosimilar strategy, which today includes five products in development, including four under the Amgen/Actavis collaboration.”
Dublin-based Actavis is a developer and manufacturer of generic, brand, branded generic, legacy brands and over-the-counter pharmaceutical products, with commercial operations in approximately 60 countries. Its North American branded pharmaceuticals business is focused principally in dermatology, women’s health, urology and gastroenterology therapeutic categories.
In his new position at Impax Laboratories, Wilkinson is replacing Larry Hsu, PhD, who is retiring. Impax is a technology-based pharmaceutical company focused on the development of controlled-release and specialty-generics in addition to developing central nervous system disorder branded products.